With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 ...

The company said, “Over the near term, Moderna (MRNA) will continue to build a large seasonal vaccine franchise targeting at-risk populations and ...

Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company ...

CAMBRIDGE, MA / ACCESSWIRE / May 2, 2023 /Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to establish an ...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a ...

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

Moderna announced Tuesday that it has hired Chantal Friebertshäuser as SVP of commercial for Europe, the Middle East and Canada. Most recently, Friebertshäuser served in global commercial leadership ...

Corinne Le Goff has been appointed president, CEO and director at Celsion, the clinical-stage biotech announced. Michael Tardugno, the company’s former president and CEO, will continue to serve as ...

CAMBRIDGE, MA / ACCESSWIRE / April 27, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Arpa Garay will join ...

New capabilities strengthen U.S. production, completing Moderna’s domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled ...